Company intelligence
RapidAccess.ai
Flexible Analytics for Pricing & Reimbursement
About RapidAccess.ai
RAPID Access is an AI-powered market access intelligence platform designed for pharma and biotech teams that need faster, more precise, and more actionable insight across the payer landscape. By consolidating key reimbursement and access signals into a single platform, RAPID helps teams cut through fragmentation, reduce manual tracking, and move beyond static assumptions. The platform addresses persistent market access challenges, including manual monitoring of CDA-AMC and pCPA activity, time-intensive review of reimbursement reports, ongoing competitive intelligence needs, and the difficulty of refining strategy as new analogues or evidence emerge. RAPID offers live views of submission and agency trends, structured file briefs for efficient review, customizable performance analyses by indication and asset, and flexible analytics that help teams test assumptions and identify relevant comparators with speed. Ultimately, RAPID enables teams to spend less time on administrative work and more time on strategy, explore trends across 60+ parameters, and generate rapid, tailored answers to complex market access questions.
Verified activity
Signals from RapidAccess.ai
3 published signals
Research & Knowledge
RapidAccess.ai published evaluations from INESSS, six new CDA-AMC files opened for input, and a pCPA negotiation that closed without an agreement.
Reported by RapidAccess.ai
Research & Knowledge
RapidAccess.ai published clinical case recommendations for tirzepatide in type 2 diabetes and chronic weight management, including a price reduction recommendation for the 5 mg dose.
Reported by RapidAccess.ai
Research & Knowledge
RapidAccess.ai published clinical case recommendations for tirzepatide in chronic weight management, including a reimbursement request for a restricted population of BMI ≥ 27 with prediabetes.
Reported by RapidAccess.ai